

## 僧帽弁手術中のアブレーションの有益性 (Abstract 408-10)

僧帽弁手術中のアブレーションにより少なくとも1年間は心房細動発作が減少する

Ablation during mitral valve surgery reduces atrial fibrillation episodes for at least a year

僧帽弁手術施行中にアブレーションを施行された心房細動患者は、僧帽弁手術のみを施行された患者に比べその後1年間の心房細動発作が少なかったとのスタディ結果が第64回 American College of Cardiology年次集会で発表され、*New England Journal of Medicine*オンライン版に掲載された。このスタディは僧帽弁手術を施行される患者260人を僧帽弁手術単独または僧帽弁手術と外科的アブレーションの両者施行群にランダムに割り付けた。スタディ参加者全員が持続性または長期持続性心房細動を有していた。アブレーションと僧帽弁手術を施行された患者のうち63%が術後6、12か月の時点で心房細動を有していなかったのに対し、僧帽弁手術のみを施行された患者のうちこれらの時点で心房細動を有していなかったのは29%であった。しかしまたこの解析から、僧帽弁手術にアブレーションを含めることによるマイナス面がある可能性も明らかになった。僧帽弁手術とともにアブレーションも施行された患者は術後1年間にペースメーカー埋め込みを必要とする確率が2.5倍高かった。この差の理由は不明であり、さらなる研究が必要である。

### Full Text

Patients with atrial fibrillation who received ablation while they were already undergoing mitral valve surgery had fewer episodes of atrial fibrillation a year later compared to patients who had the valve surgery alone, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session and published online in the *New England Journal of Medicine* at the time of presentation.

The patients who received ablation along with mitral valve surgery had no more deaths, adverse cardiac events or hospitalizations than patients who only received the valve surgery alone, but they were more likely to require a pacemaker.

The study, which included 260 patients within the Cardiothoracic Surgical Trials Network, a clinical research network involving 20 U.S. and Canadian hospitals, is the first appropriately powered randomized clinical trial to assess the use of ablation in patients already undergoing mitral valve surgery. Half of the patients were randomly assigned to receive mitral valve surgery alone, while the other half also received surgical ablation. All of the study participants had persistent or long-standing persistent atrial fibrillation and were undergoing surgery to repair or replace the heart's mitral valve.

Of the patients who received ablation and mitral valve surgery, 63 percent were free from atrial fibrillation at six and 12 months after surgery, while 29 percent of patients who received mitral valve surgery alone were free from atrial fibrillation at those time points.

"Although surgeons are widely performing ablation at the time of mitral valve surgery, there is a great deal of variation with regard to when it is done, how it is done and which patients receive it," said Marc Gillinov, M.D., the Judith Dion Pyle Chair in Heart Valve Research at Cleveland Clinic and the study's lead author. "We sought to conduct a well-designed randomized controlled trial to answer fundamental questions about whether this procedure is successful and how it is best done."

In the absence of strong clinical guidance regarding the use of ablation with mitral valve surgery, the decision is left largely up to physician preference, Gillinov said. About two-thirds of surgeons currently perform ablation during mitral valve surgery for patients with persistent atrial fibrillation, while one-third do not.

While the patients receiving ablation were significantly more likely to be free of atrial fibrillation six and 12 months after surgery, the study showed no significant differences in rates of death, adverse cardiac events or hospitalization. Patients receiving the mitral valve surgery alone reported a slightly lower quality of life because more of these patients said they still experienced daily atrial fibrillation a year after the surgery.

"I think what this shows is that, in the mitral valve surgery patient who has persistent atrial fibrillation, you will achieve better rhythm control by performing ablation, without any increase in mortality or other adverse cardiac events," Gillinov said.

However, the analysis also revealed one potential downside to including ablation with mitral valve surgery. Patients receiving the ablation along with the mitral valve surgery were 2.5 times more likely to require the implantation of a pacemaker in the year following their surgery. The reason for this difference is unknown and warrants further study, Gillinov said.

Because there are several tools and techniques physicians can choose when performing surgical ablation, researchers decided to randomly assign patients receiving the ablation to either pulmonary vein isolation or a biatrial Maze lesion. The analysis showed no significant differences in the outcomes for patients undergoing the two procedure types, though a larger study would help to elucidate any differences, Gillinov said.

Because patients have only been tracked for one year, the results do not yet provide a clear picture of the full spectrum of potential differences in cardiovascular outcomes. The researchers will continue to track patients to assess any long-term differences in survival, hospitalization, stroke and other outcomes.

The National Institutes of Health and Canadian Institutes for Health Research supported the design and conduct of the trial.

## ACC2015特集

[News01]

MI後の魚油に関する有益性が追加された

[News02]

心血管系リスクファクターを回避することで健康でいられる年数が増加する

[News03]

抗うつ薬は心血管転帰を改善する

[News04]

PCSK9阻害薬の長期的有効性

[News05]

2剤併用抗血小板療法を1年以上行うことの有効性

[News06]

CTAと機能的検査による転帰は同等である

[News07]

冠動脈CT造影は診断を向上させる

[News08]

CoreValveの2年間の優位性が確認された

[News09]

TAVRとともに用いられるfirst-in-field脳フィルターは有益性が認められた

[News10]

冠動脈造影の穿刺部位に関して腕は鼠径部よりも安全である

[News11]

バイパス手術は新世代ステントよりも成績が良好である

[News12]

僧帽弁手術中のアブレーションの有益性

[News13]

心不全患者はアミオダロンよりもカテーテルアブレーションの方が経過良好である

[News14]

血管形成術時のルーチン血栓除去術には有益性は認められない

[News15]

減量により心房細動が大幅に減少する

[News16]

STEMI既往者に対し完全血管形成術は安全である

[News17]

SAPIEN 3心臓弁の30日合併症率は低い